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Abstract Psoriasis is a common, disabling, chronic,
relapsing, inflammatory disorder of the skin with a
worldwide prevalence of 2–3 % in which adherence to
treatment is often poor. The majority of individuals have
limited disease that is being treated with topical medication
according to existing guidelines. Adherence rates are lower
for topical compared with systemic treatment. Low medi-
cation adherence is a major problem for patients with
chronic disorders as it results in suboptimal treatment
outcomes, increased risk for development of concomitant
diseases, inefficient use of health resources and consider-
able losses to society. However, to date no adherence-
enhancing intervention has been developed for psoriasis
patients under topical treatment. In this article, we report
the development of the topical treatment optimization
program (TTOP). The TTOP intervention aims to improve
the information given to the patients and to result in an
engaged patient–physician relationship. Application of the
TTOP intervention in daily clinical practice may lead to a
significant increase of adherence and the successful man-
agement of psoriasis and other chronic skin disorders.
Keywords Adherence  Intervention  Topical therapy 
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Introduction
Poor adherence hinders the successful treatment of chronic
conditions with efficacious available medication. Research
during the past several decades showed that, depending
upon the condition severity and the complexity of the
prescribed regimen, as many as 40 % of patients do not
adhere to the agreed treatment recommendations [50]. In
its 2003 report, the WHO recognized that ‘‘increasing the
effectiveness of adherence interventions may have a far
greater impact on the health of the population than any
improvement in specific medical treatments’’ [67].
Adherence among patients with chronic conditions is
disappointingly low, dropping most dramatically after the
first 6 months of treatment [60]. It has been suggested that,
regardless of their condition, treatment or age, only 50 %
of individuals with chronic conditions adhere to their
treatment [64]; [28, 67, 68]. Low medication adherence
leads to an inefficient use of health care resources and
therefore creates a considerable financial loss to society.
Furthermore, low adherence can result in a misleading
clinical picture in a patient’s treatment: if physicians
erroneously assume that their patients have taken pre-
scribed medication, they may make inappropriate medica-
tion and/or dosage changes, which in turn could result in
suboptimal health outcomes [50]. Importantly, it has also
been shown that poor adherence in psoriasis also increases
the risk for the development of concomitant diseases, such
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as depression, inflammation-related coronary heart disease
(CHD)/stroke, diabetes and cancer [27, 35, 58].
Psoriasis is a common skin disease with a prevalence of
*2–3 % thereby affecting around 25 million people in
North America and Europe [48]. Importantly, more than
90 % of patients have a chronic course and therefore
require continuous control of disease activity [56]. There is
a high disease burden associated with psoriasis, including
various psychosocial impairments and a significant reduc-
tion of the patient’s quality of life [2, 24, 37, 43, 49, 54].
Furthermore, the financial burden on society associated
with psoriasis is substantial [70, 72]. Therefore, successful
management of this chronic condition is crucial.
Since the majority of psoriasis patients have mild or
moderate disease, topical corticosteroids, which reduce
inflammation and decrease the rate of skin cell growth, are
the most commonly prescribed topical treatment for pso-
riasis [45].
Given the specific aspects of a topical treatment such as
the cosmetic and galenic properties as well as the time
required for and the convenience of its application it is not
surprising that in general topical treatment medication
adherence for dermatological conditions is poor, with more
than 30 % of the prescriptions to first time outpatients
never being redeemed [75]. It has been reported that the
correct number of medication applications per day declined
over time (only 77 % after 2 weeks and only 50 % after
8 weeks) [11, 67, 75]. However, for patients with psoriasis,
the reported primary adherence (redemption of initial
prescription) is even lower reaching only 65 % while
secondary adherence (correct use of medication) is even
lower with 39–73 % of the patients not using the medica-
tion as prescribed [3, 6, 8, 22, 64, 75, 81]. In a study of
almost 1,300 psoriasis patients 73 % of the patients
reported not adhering to their treatment with the most
frequently reported reasons for this being low efficacy
(27 %), poor cosmetic characteristics (29 %) and time
needed for the application (26 %) [25]. In another study
with more than 800 psoriasis patients, 72 % of who had
used topical steroids in the previous 6 months reported that
only 51 % of the patients used their topical medication as
prescribed [79]. All these studies have highlighted the high
prevalence of non-adherence among psoriasis patients
treated with a topical medication. As a consequence, the
current view of physicians on topical treatment in psoriasis
is unfortunately less favorable than it should be, if the
clinical efficacy of these treatments is considered. There-
fore, the prescription behavior of physicians is influenced
towards other, oral treatments, even when prescription
guidelines direct differently [54].
In spite of the large number of studies that have iden-
tified the importance of medication non-adherence, there
are relatively few studies reporting and designing effective
strategies to improve adherence. Given that the barriers to
medication adherence are complex and varied, solutions to
improve adherence must be multi-factorial [9]. A recent
review of the literature which was done for the Cochrane
database, reported that as far as the treatment of chronic
conditions is concerned, adherence-enhancing interven-
tions—none of which was designed for psoriasis—were not
significantly effective and therefore the authors highlighted
the need for designing comprehensive and innovative
interventions which would improve medication adherence
[28]. Furthermore, it is of high importance to design an
adherence-enhancing intervention that on the one hand can
be used at the everyday clinical routine and on the other
hand can increase a patient’s adherence to the extent that
the efficacy of the prescribed medication is observed in the
general population.
Here we report the development of an adherence-
enhancing intervention in topical treatment, termed topical
treatment optimization program or shortly TTOP. This tool
is created to address patients’ non-adherence in topical
treatment and the resulting underperformance of such
treatments in controlling psoriatic disease.
Methods
Literature search
A systematic literature search of the Medline database was
conducted in December of 2010 and January of 2011. The
aim was to generally identify important factors that influ-
ence a patient’s adherence to the prescribed treatment as
well as vital characteristics that should be incorporated in
an adherence-enhancing intervention. The search strategy
included terms for adherence (adherence, non-adherence,
compliance, non-compliance), treatment (medication, drug,
treatment, regimen), chronic conditions (chronic condi-
tions, psoriasis) and clinical trial design (clinical trial,
intervention, outcome, randomized) [(((((((((adherence)
OR non-adherence) OR compliance) OR non-compliance))
AND ((((medication) OR drug) OR treatment) OR regi-
men))) AND ((((clinical trial) OR intervention) OR out-
come) OR randomized))) AND ((chronic conditions) OR
psoriasis)], which provided 466 hits.
Patient qualitative focus group interviews
To assess all relevant aspects, needs and views of pso-
riasis patients, focus group interviews were conducted in
February and March of 2011, one with a national [4
members (3 men and 1 woman) of the German Patient’s
Psoriasis Association—Deutscher Psoriasis Bund e. V.]
and another with an international [6 members (2 from
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Germany, 1 each from Spain, Denmark, Sweden, and
The Netherlands) of the European Federation of Psoriasis
Patient Organization (EUROPSO)] patient advisory
board. Patients participating in the interviews were
selected according to their experience with topical
treatment and in general with managing psoriasis and not
according to their psoriasis condition. The aim was to
have a representative population as the TTOP interven-
tion could be applied for all patients with topical treat-
ments. Guided by an interviewer, participants were asked
to give their feedback on the following questions: ‘‘What
are the main characteristics of a typical visit of psoriasis
patients at their dermatologist?’’, ‘‘What actions could be
done in order to improve the quality of the consultations
and the treatment that the patients receive at the begin-
ning or during the course of the treatment?’’, ‘‘What
information should be provided during a dermatologist-
patient consultation?’’, ‘‘What information should be
provided during a nurse–patient consultation?’’ and
‘‘What are important points/aspects on disease and top-
ical medication to be provided in an information bro-
chure for patients?’’.
Expert qualitative focus group
A total of 11 experts from the fields of dermatology (7),
psychology (1), health economic (1) and clinical research
(2) were invited to participate in an expert panel meeting in
April 2011. The corresponding experts reviewed each
intervention element, either identified via the literature
search or during the patient interviews, and its relevance
and suitability were evaluated for inclusion or exclusion
from the newly developed adherence-enhancing interven-
tion TTOP.
The outcomes of the literature search, patient qualitative
focus group interviews and expert qualitative focus group
are presented in the results section.
Results
Literature search
Citation titles, index terms, and abstracts were screened to
identify potentially relevant articles, which were subse-
quently retrieved for full-text review. Original articles were
selected if they reported the development and application of
at least one adherence-enhancing intervention in the treat-
ment of chronic medical conditions [5, 13, 17, 19, 29, 32,
36, 38, 41, 44, 53, 57, 59, 61, 66, 69, 71, 74]. Furthermore,
the selected studies were required to report one measure
for assessing medication adherence and/or assessment
of one clinical outcome for showing effectiveness of the
intervention. Additionally, review articles that summarized
the current status of research on adherence-enhancing
interventions in chronic conditions were also selected and
corresponding references therein were retrieved for full-text
review [1, 26, 34, 40, 46, 55, 73, 80]. Furthermore, 14
publications, which were not identified via the literature
search but which were known to the authors as being rele-
vant, were included in the pool of the literature retrieved for
full-text review [10, 15, 20, 21, 23, 31, 39, 47, 52, 62, 63,
65, 76, 77]. Given that none of the already published
adherence-enhancing interventions were specific for psori-
asis it was difficult to identify factors specific to psoriasis or
its treatment.
In summary, the following areas were identified as being
important to be incorporated in an adherence-enhancing
intervention: simplification of regimen, understanding of
treatment instructions, comorbidity and overall health sta-
tus, patient-reported outcomes, quality of life, treatment
satisfaction, quality of patient–doctor relationship, patient
education, information regarding the condition and its
treatment, self-reported adherence, objective assessment of
adherence and involvement of patient in treatment deci-
sion-making process.
Subsequently, intervention elements were created that
were included within the aforementioned areas. These
areas were presented for discussions with both the patient
and the expert qualitative focus groups.
Patient qualitative focus group interviews
Discussions with the national patient board resulted in the
proposal to create a checklist specifying and allocating
necessary tasks (either for the treating physician or other
health care professionals), which should be followed dur-
ing the patients’ consultations both at the start of the
treatment as well as during the course of the treatment.
Based on the patients’ proposal these checklists should
instruct the health care provider: (1) to provide information
regarding the disease, potential treatments and potential
further treatments in case of disease exacerbation, (2) to
explain actual chosen therapy and motivate the patient to
ask questions and communicate expectations regarding the
therapy, (3) to pose questions on skin condition and other
areas of the patient’s life and (4) to hand out information
material. Second proposal, originating from the patient
interviews was to install a function in the practices/hospi-
tals serving as contact point for the patients between the
regular visits.
The proposals of the patients from the national board
were taken into account so that at the time of the interna-
tional patient board, a preliminary checklist for physicians
(or other health care professional) and a preliminary patient
questionnaire concerning the topical treatment were
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created. Both preliminary tools, which additionally inclu-
ded items resulting from the literature search, were dis-
cussed during the interview with the international patient
board. Regarding the checklist, new aspects which were
identified during the interview were included in the
checklists which were later placed for discussion during the
expert qualitative focus group. Regarding the question-
naire, all points collected during the meeting were covered
by the current items of the item pool. Later analysis of the
results of these interviews revealed that all aspects reported
by the patients were already included in the element pool
that had been created from the literature search. In general,
the patients from both boards expressed their wish for a
holistic approach from health care providers, with time to
talk and learn about the disease and the therapy, both at the
start of a treatment as during the course of the therapy/
disease.
Expert qualitative focus group
All items gathered by either the literature search or by
the qualitative patient focus group interviews were pro-
vided to the expert focus group and discussed. Regarding
the task and allocation guidelines the experts discussed
and shorted out all of the different items and finalized
the content as well as structure of two guidelines; one
intended to be used by the treating physician and one to
be used by the nurse. Regarding, the patient question-
naire once again all items were discussed and the experts
decided which of these should be included in the final
version of the questionnaire. Importantly, it was pro-
posed to rephrase all items as statements rather than
questions.
Furthermore, the experts discussed which other elements
should be included in the developed intervention. It was
agreed to provide the patients with information material in
the form of a patient card containing information on the
treatment and its application so that patients can remember
easily how to apply their treatment. Finally, as further
supporting information material the experts proposed to
create an information brochure regarding psoriasis and its
management. The content of all abovementioned docu-
ments is described in more detail below (section ‘‘Patient
education’’).
Resulting from the literature search, the interviews with
both patient boards and the expert advisory board meeting,
the TTOP has been developed with the aim to firstly
qualitatively and quantitatively increase the information
provided to the patients regarding their condition and its
available treatment and secondly to improve the patient–
doctor relationship to the extent that the communication
between the two parties is optimal and does not hinder the
patient’s adherence.
The TTOP intervention and its elements
Patient education
The first key element of the developed TTOP intervention
involves educating the patients regarding their condition
and its treatment.
According to TTOP, patients receive extensive infor-
mation regarding psoriasis and the treatment that is pro-
vided to them during one-to-one consultations with the
treating physician as well as a nurse or other responsible
members of the staff. For that purpose, standardized
communication guidance in form of checklists, one for
treating physicians (Online Resource 1) and one for nurses
(Online Resource 2), was compiled resulting from the
patient boards and expert advisory boards. At the beginning
of their treatment patients are being educated by the phy-
sician regarding psoriasis’ pathophysiology (i.e., immune
driven disease), regarding its chronicity (i.e., life-long,
chronic), its comorbidity and various other facts associated
with their condition (i.e, non-infectious, non-malignant).
Furthermore, the physician explains to the patients how the
psoriasis severity grade is being assessed according to the
clinical manifestation of their condition and the severity of
symptoms that each patient exhibits.
Subsequently, the physician discusses with the TTOP
intervention patients the available treatments for psoriasis
(i.e., topical, systemic and photo treatment) and the char-
acteristics of each treatment are compared against each
other. The physician then informs the patients that
according to their condition severity, prescription of topical
treatment is the ideal choice for them. In this way, the
patients get involved by participating in the treatment
decision-making process. Following this information, the
physician introduces to the patient the study medication
regarding its ingredients, considerations that need to be
made before, during and after its application and regarding
realistic treatment expectations. Patients are encouraged to
consult the package information leaflet which accompanies
the medication and are trained by the nurse how to cor-
rectly apply the medication to their affected areas. Addi-
tionally, within the TTOP intervention patients are also
provided with a pocket card that describes the regimen and
mode of application of their topical treatment. Further-
more, on the 7th and 21st day after treatment start patients
are contacted—either by phone or email—by the nurse to
be reminded to apply their topical medication daily.
Importantly, to actively involve the patients in their treat-
ment and to get their views and opinions regarding their
treatment throughout its duration two novel questionnaires
have been developed which aim to enable the early iden-
tification of potential non-adherent behaviors and adher-
ence-enhancing factors and to assess the patient’s
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satisfaction with the current topical treatment: the Topical
Treatment Adherence Questionnaire (TTAQ) and the
Patient Preference Questionnaire (PPQ). The TTAQ, con-
taining 59 items, assesses the following areas of the
patient’s evaluation of topical therapy: ‘‘Patient’s benefit
from treatment’’, ‘‘Knowledge, communication and rela-
tionship with the physician’’ and ‘‘Patient satisfaction with
treatment’’. The PPQ, containing 10 items, was developed
to collect data on the patients’ preference to the current
treatment in comparison to their previous treatments. For
both questionnaires, all items are scaled in a 4-point Likert
format (0 = strongly disagree, 1 = disagree, 2 = agree
and 3 = strongly agree), with a supplementary option to
tick ‘‘Does not apply to me’’. The development of TTAQ
and PPQ was based on a systematic literature review,
patient focus interviews and expert focus groups and is
described in detail in a separate publication [82]. Finally,
written information material is provided to the TTOP
intervention patients in form of a brochure. Importantly,
the brochure’s text is formatted in Questions & Answers
aiming to increase its comprehensibility to the patients.
The ‘‘TTOP brochure’’ contains short summaries of
important information regarding psoriasis: ‘‘What is pso-
riasis?’’, ‘‘What causes psoriasis?’’, ‘‘Is there a cure for
psoriasis?’’, ‘‘How does clothing affect psoriasis?’’, ‘‘What
can trigger psoriasis?’’, ‘‘What health complications are
associated with psoriasis?’’, ‘‘Is psoriasis linked to other
diseases?’’, ‘‘Does having psoriasis affect lifestyle or
quality of life?’’, ‘‘Why does psoriasis itch?’’, ‘‘Is psoriasis
contagious?’’, as well as information regarding the treat-
ment and types of treatment of psoriasis, and lifestyle
including physical activity. Through all these intervention
elements it is ensured that the patient understands thor-
oughly the treatment instructions, has realistic treatment
expectations, has no anxieties over the complexity of the
regimen and is reminded how and when to apply the pre-
scribed medication.
Patient–health care provider relationship
The second key element of the TTOP intervention aims at
improving the relationship and communication between the
patients and their health care provider; both their treating
physician and the nurse.
To that end, both the physician and the nurse are
applying a number of approaches to improve their rela-
tionship with the patients treated according to the TTOP
intervention. For this purpose, we have developed a guide
(‘‘A General Patient Encounter Guide’’), which has been
adapted from E.E. Uhlenhake et al. 2010 [78], stating
several general considerations that need to be made during
the encounter of the health- care providers with their
patients (Online Resource 3). The physician and nurse are
among others instructed to greet politely the patients at the
beginning and the end of the visit, to lean forward towards
the patient showing that they are engaging in the conver-
sation with them, to provide enough time for the consul-
tation, to ask open-ended questions (e.g., ‘‘How are you
today?’’, ‘‘Is there anything else?’’), to not interrupt the
patients, to ensure that the patients’ needs are acknowl-
edged, to be open, honest and responding regarding any
aspect of the treatment and to ask them how is their life
affected by their condition and offer sympathy. Further-
more, as mentioned above according to TTOP the patients
are informed to a high extent regarding their condition, the
prescribed treatment and are encouraged to actively par-
ticipate during their consultation. All these approaches aim
at having the patients feel that their physician/nurse takes
enough time to care, listen and respond to them thus
establishing a personal relationship with them which is
based on collaboration, trust, sympathy and understanding.
Importantly, in order to feel supported by their physician,
TTOP intervention patients are provided with the possi-
bility to e-mail or telephone their health care provider in
between visits (helpdesk), if specific questions/problems
arise that the patient wishes to clarify and discuss. Finally,
at each consultation the importance of adhering to the
treatment is reminded to the patients and their feedback is
being asked regarding potential challenges that they have
encountered during their treatment.
Discussion
No single intervention strategy could improve adherence of
all patients. Discussions with both the German as well as
the International patient boards indicated that a number of
different factors are considered by different patients as
being important for adhering to the prescribed treatment.
Several studies have shown that by just increasing the
information given to the patients or by solely improving the
patient–physician communication or even by simplifying
the prescribed treatment will not result in increasing the
adherence for all patients [50]. Moreover, several studies
have attempted to describe, summarize and categorize
factors and predictors of non-adherence as well as medi-
cation adherence-enhancing factors [3, 7, 9, 12, 16, 30, 33,
50, 51, 60, 64]. According to these studies, adherence is a
multidimensional phenomenon determined by the interplay
of a large number of factors which mainly fall into the
following three categories: therapy-related factors (e.g.,
complexity of the medical regimen, interference of treat-
ment with daily routine and duration of treatment), patient-
related factors (e.g., severity of symptoms, level of dis-
ability, existence of comorbidity and misunderstanding of
treatment instructions) and health care-related factors (e.g.,
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quality of the patient–health care provider relationship,
duration of consultations and capacity of the system to
educate patients and provide follow-up). Therefore, the
TTOP intervention was designed to target a multitude of
these factors from all identified areas in order for the
highest possible increase in medication adherence to be
achieved.
Importantly, it is recognized that adherence and the act
of following a treatment (e.g., ingesting a pill or applying a
topical medication) is a certain a behavior. Therefore,
theories of behavior change should be applied and taken
into account upon designing an adherence-enhancing
intervention [16]. Various elements from change behavior
theories were addressed when developing the TTOP
intervention. Since these theories share the central
assumption that people are capable of forethought, plan-
ning, and rational decision making and that people expe-
rience their decision making and self-regulation as part of a
dynamic social learning process [7] in the TTOP inter-
vention patients are provided with an increased amount of
information that would allow them to carefully think and
decide that following their prescribed treatment and hence
being adherent is a necessary behavior and is a decision
originating from them.
The first characteristic of the developed intervention is
to educate the patients regarding their condition and its
treatment. Adjunctive treatment in the form of patient
education is now widely advocated in chronic disease
management and has been shown to be a simple but
effective means of supplementing conventional treatment
and contributing to satisfaction with care as well as treat-
ment adherence [64]. By increasing the amount of infor-
mation that they receive, patients feel that they are actively
participating in improving their condition. Studies have
shown that adherence is significantly enhanced by patients’
involvement and participation in their care. Based on the
self-efficacy theory, where it is assumed that perceived
self-efficacy is about what individuals believe they can do
with the skills they have or what they can learn in various
circumstances and situations [7], it has been suggested that
the more empowered patients feel, the more likely they are
to be motivated to manage their disease and adhere to their
medications [9, 16]. Importantly, studies have shown that a
major contributor to non-adherence is patients’ forgetful-
ness to take (or how to take) their prescribed medication
[50]. Therefore, TTOP intervention patients are being
reminded (either from their pocket cards or by directly
contacting them) to adhere to their treatment.
The second characteristic of the TTOP intervention is
improving the relationship of the patients with their health
care provider. Several studies have reported that patients
who report a communicative, understanding and encour-
aging relationship with their physician tend to be more
motivated to adhere to their treatment [50]. The substan-
tially improved adherence of these patients highlights the
important role of physicians in increasing their patients’
adherence [9]. Effective communication is of course the
key to a good physician–patient relationship. It is proposed
that a patient-centered approach that consists of participa-
tion, engagement, encouragement, collaboration, negotia-
tion, and sometimes compromise results in patients feeling
responsible to adhere to their treatment and thus in optimal
treatment outcomes [9, 50].
To potentially show the importance of an optimized
contact between the patient and health care professional in
increasing topical treatment adherence, the TTOP is cur-
rently being compared to standardized minimal regular
care in an international phase IV study with *2,000
patients. Assessing the effectiveness of the TTOP inter-
vention should be multi-factorial. Initially, a very impor-
tant aspect to be considered should be the standardization
of the medication as it has been shown that one important
factor leading to poor adherence is the frustration of the
patient with messy and inconvenient formulations of topi-
cal therapies, leading from poor use of medication to not
using the medication and/or not collecting prescriptions [4,
75]. The prescribed regimen has also been shown to sig-
nificantly affect adherence with once-daily regimens
resulting in 84 % adherence while for thrice-daily regi-
mens reported adherence is only 59 % [50]. Therefore, it is
of high importance that patients treated according to the
TTOP intervention as well as patients receiving the stan-
dardized minimal regular care should be treated with a
highly efficacious topical medication with a simplified
regimen.
Furthermore, to assess the effectiveness of the TTOP
intervention, it is imperative that the patient’s adherence as
well as the medication’s efficacy is assessed. Adherence
can be assessed in a variety of ways including pill counts,
self-reports or patient diaries, physician reports, electronic
monitoring of medication use, biochemical assays and
biologic markers, medical record/chart and electronic
pharmacy records [50, 51]. Ideally, adherence should be
assessed in a two-way approach, both objectively (e.g.,
weight of used topical medication) as well as subjectively
(e.g., self-reported patient adherence). The aim would be to
assess if adherence rates of patients treated according to the
TTOP intervention are higher than the ones of patients
receiving the standardized minimal regular care. Further-
more, the improvement in their condition severity should
be assessed. In addition to the commonly used clinical
assessment methods (e.g., PGA, BSA) the patients should
also be asked to self-assess their condition severity. To that
end, we have developed a novel method that can be used
for assessing psoriasis severity by the patients. This new
tool is termed Patient’s Global Assessment or short PsGA
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and it is the patient equivalent of PGA (Table 1). Impor-
tantly, patients’ views and opinions should be regularly
sought out by use of the newly developed patient ques-
tionnaires TTAQ and PPQ. Since there are the significant
differences between the TTOP intervention and the stan-
dardized minimal regular care and to assure that patients
will receive differential treatment, communication guide-
lines in form of checklists have been created. These
guidelines define the structure and the sequence of the tasks
that should be performed during each patient’s visit and
according to the treatment that this patient is receiving
(TTOP intervention or standardized minimal regular care).
Moreover, it is also defined who would be responsible for
performing which task (e.g., the nurse is responsible to
train the patient how to correctly apply the medication).
For the TTOP intervention, these guidelines shall also
assist in the building of a more personalized relationship
with the patients over time and provide ample opportunity
for the health care professional to take the patient-desired
holistic approach: helping the patient to learn about his
disease and the treatment offered. Since the TTOP inter-
vention is an adherence-enhancing intervention which
depends on the increased amount of information and
communication between physician and patient it is evident
that consultation of patients according to TTOP has to be
more time consuming than that of standardized regular
care. To be able to assess how time consuming the
implementation of the TTOP intervention into the daily
routine practice would be, the study personnel at all study
sites should be asked to document the time required for the
consultation of each patient. Finally, to be able to assess
which elements have to be included or not during the
intervention’s implementation into daily practice, patients
should also be asked to rank the different elements of the
TTOP (helpdesk, patient brochure, one-to-one conversa-
tions with study nurse, one-to-one conversations with
dermatologist, reminders sent to patient) using a 5-point
Likert scale.
Given that when patients are more satisfied with their
medical visits, they tend to experience better recall of
information that they receive [18] the aim of the TTOP
intervention is just that; having the patients leave the doctor’s
office feeling satisfied with the time which was provided to
them, the information that they received and the communi-
cation with their health care provider. As a consequence, the
patients are more likely to adhere to their treatment achieving
thus optimal treatment outcomes [14, 64].
The results of the ongoing study assessing the effec-
tiveness of TTOP are eagerly awaited and will be published
after termination of the study. In addition, it will also be
interesting to determine what could/must be transferred
into the daily routine clinical practice and how practical or
time consuming such a transfer might be. In the long run,
we aim to be able to have the key elements of the TTOP
program being applied in the daily clinical routine leading
hence to a significant increase of adherence and improve-
ment of the severity grade of their chronic condition for the
patients.
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